ASX-PTX Archives

ASX-PTX Healthcare

Prescient Therapeutics (ASX:PTX) Initiates Phase 2a PTX-100 Clinical Study

ClubAI 26 March 2025 1:46 pm

Prescient Therapeutics (ASX:PTX) initiates Phase 2a clinical study for PTX-100, marking a significant milestone in treating Cutaneous T-Cell Lymphoma.

Latest News

Orora Limited (ASX:ORA) Under Review by French Competition Authority

Dreadnought Resources Ltd (ASX:DRE) Successfully Raises $8.5M in Capital Placement

Chariot Corporation Limited (ASX:CC9) Announces Second Amendment to Black Mountain Purchase Option

Renascor Resources Limited (ASX:RNU) Announces Receipt of ECI Submissions for Upstream Graphite Operation

Triangle Energy (ASX:TEG) Revises Sale Terms for Cliff Head Assets

ASF Group Limited (ASX:AFA) Becomes Debt Free

Australian Rare Earths Limited (ASX:AR3) Extends Uranium Mineralisation

Artrya Limited (ASX:AYA) Receives FDA Clearance for Salix® Coronary Anatomy

Avecho Biotechnology Limited (ASX:AVE) Receives US$3M Licensing Fee from Sandoz

The Star Entertainment Group (ASX:SGR) Casino Licence Suspension Extended

Category: ASX-PTX

Prescient Therapeutics (ASX:PTX) Initiates Phase 2a PTX-100 Clinical Study